# OnCo record ryvu-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ryvu-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ryvu-therapeutics" ;
  schema:name "Ryvu Therapeutics"@en ;
  schema:alternateName "Ryvu Therapeutics SA"@en ;
  schema:description "Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma."@en ;
  schema:url <https://onco.cc/companies/ryvu-therapeutics/>, <https://www.ryvu.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.ryvu.com>, <https://clinicaltrials.gov/search?lead=Ryvu%20Therapeutics%20SA> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "PL" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:drugs <https://onco.cc/drugs/men1703/>, <https://onco.cc/drugs/rvu120/> ;
  onco:trials <https://onco.cc/trials/nct06534437/>, <https://onco.cc/trials/nct06243458/> .